glp-1 substance use disorder receptor agonists are promising but unproven treatments for alcohol and disorders GLP-1s have transformed weight loss

And a small clinical trial in people with Alzheimers disease uncovered signs of slowed cognitive decline in those treated with the first generation GLP-1 drug liraglutide, Edisons team reports December 1 in Nature Medicine

10.1111/j.1530-0277.1996.tb01055.x 18 ChaoX.NiH

the only difference is in the dosing

Zhou J, et al

With consistent use, people often report that crow's feet, forehead lines, and other little texture issues become less obvious

339 These cases demonstrate the versatility of organoids and their consistency with in vivo therapy, and these validation results promote the ubiquitous role of organoids in drug selection and prediction for clinical treatment